Your browser doesn't support javascript.
loading
Prevalence of Bacterial Coinfection and Patterns of Antibiotics Prescribing in Patients with COVID-19: A Systematic review and Meta-Analysis
Faisal Alshaikh; Brian Godman; Amanj Kurdi; Ronald Andrew Seaton; Oula Sindi.
Affiliation
  • Faisal Alshaikh; Strathclyde Institute of Pharmacy and Biomedical Science, University of Strathclyde
  • Brian Godman; Sefako Makgatho Health Science University (SMU)
  • Amanj Kurdi; Strathclyde Institute of Pharmacy and Biomedical Science, University of Strathclyde
  • Ronald Andrew Seaton; NHS Greater Glasgow and Clyde
  • Oula Sindi; Strathclyde Institute of Pharmacy and Biomedical Science, University of Strathclyde
Preprint in En | PREPRINT-MEDRXIV | ID: ppmedrxiv-22271779
ABSTRACT
BackgroundEvidence around prevalence of bacterial coinfection and pattern of antibiotic use in COVID-19 is controversial although high prevalence rates of bacterial coinfection have been reported in previous similar global viral respiratory pandemics. Early data on the prevalence of antibiotic prescribing in COVID-19 indicates conflicting low and high prevalence of antibiotic prescribing which challenges antimicrobial stewardship programmes and increases risk of antimicrobial resistance (AMR). AimTo determine current prevalence of bacterial coinfection and antibiotic prescribing in COVID-19 patients Data SourceOVID MEDLINE, OVID EMBASE, Cochrane and MedRxiv between January 2020 and June 2021. Study EligibilityEnglish language studies of laboratory-confirmed COVID-19 patients which reported (a) prevalence of bacterial coinfection and/or (b) prevalence of antibiotic prescribing with no restrictions to study designs or healthcare setting ParticipantsAdults (aged [≥] 18 years) with RT-PCR confirmed diagnosis of COVID-19, regardless of study setting. MethodsSystematic review and meta-analysis. Proportion (prevalence) data was pooled using random effects meta-analysis approach; and stratified based on region and study design. ResultsA total of 1058 studies were screened, of which 22, hospital-based studies were eligible, compromising 76,176 of COVID-19 patients. Pooled estimates for the prevalence of bacterial co-infection and antibiotic use were 5.62% (95% CI 2.26 - 10.31) and 61.77% (CI 50.95 - 70.90), respectively. Sub-group analysis by region demonstrated that bacterial co-infection was more prevalent in North American studies (7.89%, 95% CI 3.30-14.18). ConclusionPrevalence of bacterial coinfection in COVID-19 is low, yet prevalence of antibiotic prescribing is high, indicating the need for targeted COVID-19 antimicrobial stewardship initiatives to reduce the global threat of AMR.
License
cc_by_nc_nd
Full text: 1 Collection: 09-preprints Database: PREPRINT-MEDRXIV Type of study: Observational_studies / Prognostic_studies / Rct / Review / Systematic_reviews Language: En Year: 2022 Document type: Preprint
Full text: 1 Collection: 09-preprints Database: PREPRINT-MEDRXIV Type of study: Observational_studies / Prognostic_studies / Rct / Review / Systematic_reviews Language: En Year: 2022 Document type: Preprint